4-substituted piperidine analogs and their use as subtype selective NMDA receptor antagonists
US6448270B1 · kind B1 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 13, 2000 |
| Grant date | Sep 10, 2002 |
| Priority date | — |
| Expiry date | Jun 13, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D405/06
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Novel 4-substituted piperidine analogs, pharmaceutical compositions containing the same and the method of using the 4-substituted piperidine analogs as selectively active antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes for treating conditions such as cerebral ischemia, central nervous system trauma, hypoglycemia, neurodegenerative disorders, anxiety, migraine headaches, convulsions, aminoglycoside antibiotics-induced hearing loss, chronic pain, psychosis, glaucoma, CMV retinitis, opioid tolerance or withdrawal, urinary incontinence and neurodegenerative disorders such as lathyrism, Alzheimers' Disease, Parkinsonism, and Huntington's Disease are described. Also described are novel methods for preparing 4-substituted piperidine analogs and novel intermediates of the 4-substituted piperidine analogs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.